Estudamos indução da atividade de MMP pelo peptídeo da laminina a1 AG73 em linhagem celular (CAC2) de carcinoma adenóide cístico. CAC2 cultivadas em laminina-111 com AG73 geraram espaços pseudocísticos. Inibidor de MMP diminuiu tais espaços, sugerindo ação de MMPs. CAC2 crescidas sobre AG73 mostraram aumento dose-dependente de MMP9. RNAi para MMP9 diminuiu remodelação em cultura 3D. Buscamos receptores de AG73 ligados à atividade de MMP9. CAC2 crescidas sobre AG73 exibiram colocalização de sindecan-1 e integrina b1. RNAi para sindecan-1 ou para integrina b1 geraram, isolados, redução na adesão a AG73 e nas atividades de remodelação e de protease. Duplo RNAi estudou a cooperação entre os receptores e promoveu diminuição na adesão a AG73 e na atividade de MMP. Distinção de receptores foi feita por cromatografia de afinidade e espectrometria de massa, através de colunas de afinidade com AG73 acoplado, que resultou em possíveis receptores, como integrinas b1 e aV. Sugerimos que AG73 regula adesão e secreção de MMP em células CAC2 através de sindecan-1 e integrina b1. / We studied induction of MMP activity by b1-laminin peptide AG73 in adenoid cystic carcinoma cell line (CAC2). Cells grown inside AG73-enriched laminin-111 exhibited pseudocystics spaces. MMP inhibitor decreased those spaces, suggesting MMPs action. Cells grown on AG73 showed a dose-dependent increase of MMP9 secretion. MMP9 siRNAi decreased remodeling in 3D culture. We searched for AG73 receptors regulating MMP9 activity. CAC2 grown on AG73 exhibited colocalization of syndecan-1 and b1 integrin. Syndecan-1 siRNA or siRNA b1 integrin showed reduction in adhesion to AG73 and in remodeling and protease activities. Double-knockdown explored syndecan-1 and 1 integrin cooperation and showed decrease in adhesion to AG73 and in MMP activity. Receptors characterization was made by affinity chromatography followed by mass spectrometry through AG73-affinity columns and showed putative receptors, like b1 and aV integrins. We suggest that AG73 peptide regulates adhesion and MMP secretion in CAC2 cells through syndecan-1 and b1 integrin.

Breast cancer metastasizes to the brain in 15-30% of all breast cancer cases, and metastasis is the predominant cause of breast cancer-related deaths. Patients with HER2-enriched and triple-negative breast cancers (TNBCs) are more likely to develop brain metastases. While targeted therapies exist for HER2-enriched breast cancers, there are no effective treatments for TNBCs. Thus, a greater understanding of how these cancers spread to the brain is critical. In order to spread to the brain, disseminated breast cancer cells must overcome 2 major steps—crossing the blood-brain barrier (BBB) and survival and successful colonization of the distinctive and mostly cellular brain environment. Here, we report a novel role for breast cancer cell surface receptor, Syndecan-1 (Sdc1), a heparan sulfate proteoglycan, in promoting breast cancer cell transmigration across the BBB. We found that when we silenced Sdc1 expression in a highly metastatic TNBC cell line, MDA-MB-231, these cells exhibited reduced migration across an in vitro BBB model system. Further, in an in vivo experimental model of metastasis, mice injected with MDA-MB-231 Sdc1 KD (knock-down) cells developed less brain metastases than mice injected with control non-silencing (NS1) cells. Conversely, we found that overexpression of Sdc1 in a metastatic triple-negative mouse mammary carcinoma cell line, 4T1, led to an increase in brain metastases compared to empty vector control-treated mice. We predicted that a secreted factor(s) facilitated BBB disruption that allowed for Sdc1-mediated BBB transmigration, and found that silencing Sdc1 led to decreases in the production and/or release of various cytokines and chemokines implicated in BBB permeability and transmigration. In addition to supporting BBB transmigration, through an in vitro tissue section adhesion assay, we found that Sdc1 also facilitates adhesion of breast cancer cells to the brain, and not to the liver or lungs, revealing specificity for the brain. Further, we report that Sdc1 is expressed in 81% of breast cancer patient brain metastases in our tissue microarray study and that patients with TNBC and high Sdc1 expression have shorter disease-free survival based on a study performed using data from The Cancer Genome Atlas. Taken together, we predict that breast cancer cell Sdc1-regulated cytokines and chemokines promote BBB permeability and/or support transmigration to facilitate breast cancer metastasis to the brain. We also provide evidence for breast cancer-secreted extracellular vesicles, namely exosomes, in supporting the formation of a pro-metastatic brain environment. We compared exosomes derived from the metastatic 4T1 mouse mammary carcinoma cell line to a non-metastatic counterpart, the 67NR cell line, to assess their microRNA and protein composition and their effect(s) on recipient astrocytes, known mediators of brain metastasis. We found that there are inherent differences in both the microRNA and protein cargo from the metastatic 4T1 cells compared to the non-metastatic 67NR cells, whereby the metastatic 4T1 cells contained various tumor-promoting microRNAs and proteins, and also contained 4.5-fold more protein than the non-metastatic 67NR cells. Mouse astrocytes treated with the metastatic 4T1 exosomes exhibited a shift towards a pro-metastatic phenotype, characterized by upregulation of pro-inflammatory genes, and genes associated with astrocyte reactivity and cancer, whereby 67NR exosome-treated astrocytes exhibited a response profile that overlapped with untreated controls. Overall, these findings reveal an important role for exosomes in driving changes in the brain microenvironment to create a site conducive for cancer growth. Together, both studies help to elucidate how breast cancer cells can invade and colonize the unique brain environment.

Le myélome multiple (MM) est une néoplasie B caractérisé par l'accumulation d'un clone plasmocytaire dans la moelle osseuse. Cette pathologie demeure incurable d'où la nécessité d'identifier de nouvelles cibles thérapeutiques. C'est notamment dans cette optique que nous avons initié, au sein du laboratoire, un travail de comparaison des profils d'expression génique des plasmocytes tumoraux purifiés de malades avec ceux de plasmocytes normaux et de lymphocytes B, ce qui permettra l'identification de nouvelles voies importantes pour la biologie du MM et donc de nouvelles cibles thérapeutiques potentielles.<br />Par cette approche, nous avons mis en évidence un rôle essentiel des membres de la famille BAFF/APRIL et de leurs récepteurs (BCMA, BAFF-R et TACI) dans la biologie du MM. Les cellules de MM expriment les récepteurs alors que les ligands sont principalement produits par les cellules de l'environnement médullaire. L'utilisation d'un inhibiteur spécifique de BAFF/APRIL a permis de montrer que ces facteurs de croissance sont importants pour la survie et la prolifération des cellules tumorales. TACI apparaît être le récepteur principal pour médier l'effet de BAFF et APRIL dans le MM. Une forte expression de TACI par les cellules de MM est associée à une signature génique de plasmocytes matures alors que les plasmocytes tumoraux présentant une faibles expression de TACI ont une signature génique de plasmablastes proliférants. Nous avons montré que syndecan-1, un protéoglycane à chaînes héparane sulfate joue un rôle essentiel dans la biologie du MM en permettant l'accumulation de fortes concentrations de facteurs de croissance à la surface des cellules. Nous avons identifié que syndecan-1 joue un rôle de corécepteur pour APRIL et TACI supportant ainsi la croissance des cellules de MM. <br />Ces travaux offrent de nouvelles perspectives thérapeutiques pour le MM et ont débouché sur un essai clinique de phase I/II, au CHU de Montpellier, utilisant un inhibiteur de la voie BAFF/APRIL dans le MM.

Carcinona epidermóide é um prevalente tumor de cabeça e pescoço relacionado a altas taxas de mortalidade. Neste trabalho, verificamos se AG73 (RKRLQVQLSIRT, cadeia a1), peptídeo derivado da laminina-111, regula migração, invasão e secreção de protease em células de carcinoma epidermóide oral (OSCC). Cadeia a1 da laminina e MMP9 estão expressas neste tumor in vivo e in vitro. AG73 induziu aumento da taxa migratória de células OSCC em ensaios de ferida e migração, e também estimulou invasão em ensaio em câmaras bipartites com Matrigel. Células OSCC crescidas sobre AG73 exibiram aumento dose-dependente de MMP9, detectado por zimografia. Buscamos receptores de AG73 que regulariam atividade nesta linhagem. Células OSCC crescidas sobre AG73 exibiram colocalização de sindecana-1 e integrina b1, e silenciamento desses receptores com RNA de interferência promoveu diminuição de migração e invasão dependente de AG73 nestas células. Esses resultados sugerem que sindecana-1 e integrina b1, ativados por AG73, podem regular migração, invasão e secreção de MMPs em células OSCC. / Oral squamous cell carcinoma is a prevalent head and neck tumor, related to high mortality rates. Here we studied the role played by AG73 (RKRLQVQLSIRT, a1 chain) on migration, invasion and protease secretion of a cell line (OSCC) from human oral squamous cell carcinoma. Laminin a1 chain and MMP9 are expressed in oral squamous cell carcinoma cells in vivo and in vitro. AG73 increased migratory activity of OSCC cells, as shown by monolayer wound assays and migration assays. This peptide also stimulated cell invasion in chemotaxis chambers coated with Matrigel. OSCC cells cultured on AG73 showed a dose-dependent increase of MMP9 secretion, detected by zymography. We searched for AG73 receptors regulating activities in this cell line. OSCC cells grown on AG73 exhibited colocalization of syndecan-1 and b1 integrin, and siRNA knockdown of these receptors decreased AG73-dependent migration and invasion of OSCC cells. Our results suggest that syndecan-1 and b1 integrin signaling downstream of AG73 regulate migration, invasion and MMP secretion by OSCC cells

Estudamos indução da atividade de MMP pelo peptídeo da laminina a1 AG73 em linhagem celular (CAC2) de carcinoma adenóide cístico. CAC2 cultivadas em laminina-111 com AG73 geraram espaços pseudocísticos. Inibidor de MMP diminuiu tais espaços, sugerindo ação de MMPs. CAC2 crescidas sobre AG73 mostraram aumento dose-dependente de MMP9. RNAi para MMP9 diminuiu remodelação em cultura 3D. Buscamos receptores de AG73 ligados à atividade de MMP9. CAC2 crescidas sobre AG73 exibiram colocalização de sindecan-1 e integrina b1. RNAi para sindecan-1 ou para integrina b1 geraram, isolados, redução na adesão a AG73 e nas atividades de remodelação e de protease. Duplo RNAi estudou a cooperação entre os receptores e promoveu diminuição na adesão a AG73 e na atividade de MMP. Distinção de receptores foi feita por cromatografia de afinidade e espectrometria de massa, através de colunas de afinidade com AG73 acoplado, que resultou em possíveis receptores, como integrinas b1 e aV. Sugerimos que AG73 regula adesão e secreção de MMP em células CAC2 através de sindecan-1 e integrina b1. / We studied induction of MMP activity by b1-laminin peptide AG73 in adenoid cystic carcinoma cell line (CAC2). Cells grown inside AG73-enriched laminin-111 exhibited pseudocystics spaces. MMP inhibitor decreased those spaces, suggesting MMPs action. Cells grown on AG73 showed a dose-dependent increase of MMP9 secretion. MMP9 siRNAi decreased remodeling in 3D culture. We searched for AG73 receptors regulating MMP9 activity. CAC2 grown on AG73 exhibited colocalization of syndecan-1 and b1 integrin. Syndecan-1 siRNA or siRNA b1 integrin showed reduction in adhesion to AG73 and in remodeling and protease activities. Double-knockdown explored syndecan-1 and 1 integrin cooperation and showed decrease in adhesion to AG73 and in MMP activity. Receptors characterization was made by affinity chromatography followed by mass spectrometry through AG73-affinity columns and showed putative receptors, like b1 and aV integrins. We suggest that AG73 peptide regulates adhesion and MMP secretion in CAC2 cells through syndecan-1 and b1 integrin.

No description available.

La possibilité de programmer une cellule dans le but de produire une protéine d’intérêt est apparue au début des années 1970 avec l’essor du génie génétique. Environ dix années plus tard, l’insuline issue de la plateforme de production microbienne Escherichia coli, fut la première protéine recombinante (r-protéine) humaine commercialisée. Les défis associés à la production de r-protéines plus complexes et glycosylées ont amené l’industrie biopharmaceutique à développer des systèmes d’expression en cellules de mammifères. Ces derniers permettent d’obtenir des protéines humaines correctement repliées et de ce fait, biologiquement actives. Afin de transférer le gène d’intérêt dans les cellules de mammifères, le polyéthylènimine (PEI) est certainement un des vecteurs synthétiques le plus utilisé en raison de son efficacité, mais aussi sa simplicité d’élaboration, son faible coût et sa stabilité en solution qui facilite son utilisation. Il est donc largement employé dans le contexte de la production de r-protéines à grande échelle et fait l’objet d’intenses recherches dans le domaine de la thérapie génique non virale. Le PEI est capable de condenser efficacement l’ADN plasmidique (vecteur d’expression contenant le gène d’intérêt) pour former des complexes de petites tailles appelés polyplexes. Ces derniers doivent contourner plusieurs étapes limitantes afin de délivrer le gène d’intérêt au noyau de la cellule hôte. Dans les conditions optimales du transfert de gène par le PEI, les polyplexes arborent une charge positive nette interagissant de manière électrostatique avec les protéoglycanes à héparane sulfate (HSPG) qui décorent la surface cellulaire. On observe deux familles d’HSPG exprimés en abondance à la surface des cellules de mammifères : les syndécanes (4 membres, SDC1-4) et les glypicanes (6 membres, GPC1-6). Si l’implication des HSPG dans l’attachement cellulaire des polyplexes est aujourd’hui largement acceptée, leur rôle individuel vis-à-vis de cet attachement et des étapes subséquentes du transfert de gène reste à confirmer. Après avoir optimisées les conditions de transfection des cellules de mammifères CHO et HEK293 dans le but de produire des r-protéines secrétées, nous avons entrepris des cinétiques de capture, d’internalisation des polyplexes et aussi d’expression du transgène afin de mieux comprendre le processus de transfert de gène. Nous avons pu observer des différences au niveau de ces paramètres de transfection dépendamment du système d’expression et des caractéristiques structurelles du PEI utilisé. Ces résultats présentés sous forme d’articles scientifiques constituent une base solide de l’enchaînement dans le temps des évènements essentiels à une transfection efficace des cellules CHO et HEK293 par le PEI. Chaque type cellulaire possède un profil d’expression des HSPG qui lui est propre, ces derniers étant plus ou moins permissifs au transfert de gène. En effet, une étude menée dans notre laboratoire montre que les SDC1 et SDC2 ont des rôles opposés vis-à-vis du transfert de gène. Alors que tous deux sont capables de lier les polyplexes, l’expression de SDC1 permet leur internalisation contrairement à l’expression de SDC2 qui l’inhibe. De plus, lorsque le SDC1 est exprimé à la surface des cellules HEK293, l’efficacité de transfection est augmentée de douze pourcents. En utilisant la capacité de SDC1 à induire l’internalisation des polyplexes, nous avons étudié le trafic intracellulaire des complexes SDC1 / polyplexes dans les cellules HEK293. De plus, nos observations suggèrent une nouvelle voie par laquelle les polyplexes pourraient atteindre efficacement le noyau cellulaire. Dans le contexte du transfert de gène, les HSPG sont essentiellement étudiés dans leur globalité. S’il est vrai que le rôle des syndécanes dans ce contexte est le sujet de quelques études, celui des glypicanes est inexploré. Grâce à une série de traitements chimiques et enzymatiques visant une approche « perte de fonction », l’importance de la sulfatation comme modification post-traductionnelle, l’effet des chaînes d’héparanes sulfates mais aussi des glypicanes sur l’attachement, l’internalisation des polyplexes, et l’expression du transgène ont été étudiés dans les cellules CHO et HEK293. L’ensemble de nos observations indique clairement que le rôle des HSPG dans le transfert de gène devrait être investigué individuellement plutôt que collectivement. En effet, le rôle spécifique de chaque membre des HSPG sur la capture des polyplexes et leur permissivité à l’expression génique demeure encore inconnu. En exprimant de manière transitoire chaque membre des syndécanes et glypicanes à la surface des cellules CHO, nous avons déterminé leur effet inhibiteur ou activateur sur la capture des polyplexes sans pouvoir conclure quant à l’effet de cette surexpression sur l’efficacité de transfection. Par contre, lorsqu’ils sont présents dans le milieu de culture, le domaine extracellulaire des HSPG réduit l’efficacité de transfection des cellules CHO sans induire la dissociation des polyplexes. Curieusement, lorsque chaque HSPG est exprimé de manière stable dans les cellules CHO, seulement une légère modulation de l’expression du transgène a pu être observée. Ces travaux ont contribué à la compréhension des mécanismes d'action du vecteur polycationique polyéthylènimine et à préciser le rôle des protéoglycanes à héparane sulfate dans le transfert de gène des cellules CHO et HEK293. / With the aim to express a protein of interest, the transfer of exogenous genetic material into host cells was established in early 70s with the development of genetic engineering. Approximately ten years later, insulin was the first human recombinant protein (r-protein) produced at large scale in Escherichia coli and commercialized. Challenges associated with the production of more complex and glycosylated r-proteins brought the pharmaceutical industry to develop mammalian expression platforms. Thus, the expressed r-proteins are correctly folded and biologically actives. As a means to transfer genetic materials of interest into mammalian cells, the synthetic vector polyethylenimine (PEI) is probably the most popular due to its efficacy, ease of use, cost-effectiveness and stability in solution. Consequently, PEI is largely employed for the production of r-proteins by large scale and extensively studied in the context of non-viral gene therapy. PEI is capable to efficiently condense plasmid DNA (expression vector containing the gene of interest) to form small nanoparticles termed polyplexes. The latter must circumvent several steps to deliver the gene of interest to the cell nucleus. When formed at the optimum conditions, polyplexes exhibit a net positive charge which can interact electrostatically with negatively charged heparan sulfate proteoglycans (HSPG) located at the cell surface. There are two major families of HSPG that are largely expressed at the surface of mammalian cells: the syndecans (4 members, SDC1-4) and the glypicans (6 members, GPC1-6). Although it is generally accepted that HSPG are involved in the binding of polyplexes, their individual role toward polyplex binding and the subsequent phases of gene transfer need to be confirmed. Following optimization of the mammalian CHO and HEK293 cells transfection conditions, we undertook an in-depth study of polyplexes uptake, internalization kinetics, as well as transgene expression kinetics with the aim to better understand the mechanisms underlying gene transfer. We observed several contrasting differences between the two cell lines and the type of PEI used. Our results presented as a scientific article, establish strong basis of the gene transfer process over-time. Every cell type possesses its own expression profile of HSPG which can display individual potency toward gene transfer. Indeed, a preliminary study conducted in our laboratory showed that SDC1 and SDC2 have distinct features with regard to gene transfer. While both are capable to bind polyplexes at the cell surface, the expression of SDC1 enhances polyplexes internalization whereas the expression of SDC2 drastically inhibits it. Furthermore, when SDC1 is expressed at the surface of HEK293 cells, the transfection efficiency is increased by twelve percent compared to control cells. By using the ability of SDC1 to mediate efficient internalization of polyplexes, we have studied the intracellular traffic of SDC1 / polyplexes complexes. Our conclusions lead to new insights concerning the path by which polyplexes can mediate efficient transfection. In the context of gene transfer, HSPG have been essentially studied in their entirety. Although the role of syndecans is the subject of some studies, that of glypicans is unexplored. Thanks to a series of chemical and enzymatic treatments leading to « loss of functions », the importance of sulfation as post-translational modification, the effect of HS chains and of glypicans on the attachment, internalization of polyplexes as well as transgene expression were investigated in CHO and HEK293 cells. Taken together, our observations indicate clearly that the role of HSPG should be investigated individually instead of collectively. Consequently, the individual potency of each HSPG member regarding gene transfer remains to be defined. We demonstrated that, in fact, the transient expression of some HSPG in CHO cells have a beneficial effect on polyplexes uptake while others have a negative effect. Unfortunately, this method did not allow concluding about their effect on transfection efficacy. However, when present in the culture medium, the extracellular domain of HSPG decreases transfection efficacy of CHO cells without inducing polyplexes dissociation. Strangely, when each HSPG is stably expressed in CHO cells, only subtle modulations of the gene expression level were observed. This study contributed to a better understanding of the mechanisms underlying PEI mediated gene transfer in CHO and HEK293 cells and clarify the role of HSPG in gene transfer.

An injured vascular system has a substantial impact on an individuals overall health, and an understanding of the mechanisms that underlie blood vessel pathophysiology is required for the development of rational and effective treatment strategies. The phenotypic modulation of smooth muscle cells (SMC) during vascular injury, characterized by altered adhesion, migration and synthetic behavior, plays an important role in the eventual outcome. Specifically, the ability of SMCs to adhere to and remodel their extracellular environment via regulation of the syndecan class of cell adhesion molecules dictates the response of the vascular wall to local injury. The effect of in vitro syndecan-4 regulation on SMC adhesion was investigated through the use of a glass microsphere centrifugation assay, and an antisense-mediated reduction in gene expression was found to correlate with decreased adhesive strength. Regulation of syndecan-1, syndecan-2, and syndecan-4 gene expression was observed experimentally by mechanical strain of SMCs. Using real-time polymerase chain reaction (PCR), the kinetics of both static and cyclic mechanical strain were found to modify the gene expression in a time and strain magnitude-dependent manner unique to each syndecan. In particular, the responses of syndecan-4 were acute, but transient, while the evolution of syndecan-1 and syndecan-2 regulation was delayed by comparison. Mechanical strain also modulated syndecan-4 protein expression and ectodomain shedding, as measured by Western immunoblotting, and this effect was found, through selective inhibition, to be at least in part dependent on mitogen-activated protein (MAP) kinase signaling. In particular, intact extracellular signal-regulated MAP kinase (ERK) 1/2 and c-Jun NH2-terminal kinase / stress-activated protein kinase (JNK/SAPK) signaling pathways were found to be required for the observed strain-induced shedding. These findings offer a better understanding of syndecan function in response to mechanical strain and suggest potential new mechanisms by which physical forces may modulate vascular SMC behavior and regulation during normal physiology, pathologic conditions, and engineered arterial substitute development.